Efficacy of rasagiline in early Parkinson's disease: a meta-analysis of data from the TEMPO and ADAGIO studies

Abstract

Aim of the study: To evaluate the efficacy of rasagiline versus placebo in a pooled population of patients with early Parkinson's disease (PD). Materials and methods: TEMPO and ADAGIO were Phase III studies that evaluated the symptomatic efficacy of rasagiline versus placebo in patients with early PD. This meta-analysis included Unified Parkinson's Disease Rating Scale (UPDRS) observations from weeks 12, 24 and 36 in ADAGIO and from weeks 14 and 26 in TEMPO; TEMPO visits were recoded to weeks 12 and 24, respectively. The present analysis includes all patients who received rasagiline 1 mg/day, 2 mg/day or placebo, and had ≥1 post-baseline observations and a subgroup of patients whose baseline UPDRS Total scores were ≥27 (Upper Quartile population). Change from baseline in UPDRS scores were evaluated using mixed models repeated measures analyses. Results: Of the 1578 patients randomized to the two studies, 1546 patients met criteria for inclusion in the meta-analysis. Effects on UPDRS Total, motor and activities of daily living scores were significantly better for both doses of rasagiline compared with placebo at all time periods. The Upper Quartile population included 402 patients with a UPDRS Total score ≥27 at baseline. These patients generally demonstrated a larger magnitude of treatment effect than was seen in the full population. Conclusions: This meta-analysis confirms the efficacy of rasagiline monotherapy over 36 weeks. Although TEMPO and ADAGIO are considered studies of “very early” PD, both contained a sizeable pool of patients with more severe disease. In addition, the meta-analysis showed a larger magnitude of effect in patients with more severe baseline disease.

KEYWORDS:

• rasagiline
• Parkinson's disease
• treatment
• efficacy

Acknowledgments

The TEMPO and ADAGIO studies were supported by Teva Pharmaceutical Industries Ltd (Israel), H.Lundbeck A/S (Denmark) and Teva Neuroscience Inc. (USA). Medical writing assistance for this report was provided by Anita Chadha-Patel of ACP Clinical Communications Ltd and was funded by Teva Branded Pharmaceutical Products R & D, Inc. (Frazer, PA).

Declaration of Interests

RAH reports personal fees from Teva Pharmaceuticals, USB Biosciences, AbbVie, Novartis, Biotie Therapies, Lundbeck, Pfizer, Allergan Neuroscience, Neurocrine Biosciences, Auspex, Acadia Pharmaceuticals, Michael J Fox Foundation, AstraZeneca, Acordia Therapeutics, Impax Pharmaceuticals, Cynapsus Therapeutics, CowanTherapeutics, US WorldMeds, Acorda, Sarepta, Orion, Chelsea Therapeutics, Adagio, Northera, GE Healthcare and Eli Lilly. He also reports grants from National Parkinson Foundation, other from University of South Florida outside the submitted work.

VA, REE and EE are all employed by Teva Pharmaceuticals.

The TEMPO and ADAGIO studies were supported by Teva Pharmaceutical Industries Ltd (Israel), H.Lundbeck A/S (Denmark) and Teva Neuroscience Inc. (USA).